Angela Thedinga
Directeur/Membre du Conseil chez NKARTA, INC.
Fortune : - $ au 31/05/2024
Profil
Angela M.
Thedinga is currently an Independent Director at Nkarta, Inc. She previously served as the Chief Technology Officer at Adverum Biotechnologies, Inc. from 2019 to 2021 and as the Chief of Staff & VP-Program Management at Novartis Gene Therapies, Inc. from 2018 to 2019.
Ms. Thedinga holds a graduate degree from the Massachusetts Institute of Technology, an undergraduate degree from the University of Wisconsin, a graduate degree from The University of North Carolina at Chapel Hill, and an MBA from MIT Sloan School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NKARTA, INC.
-.--% | 13/06/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Angela Thedinga
| Sociétés | Poste | Début |
|---|---|---|
| NKARTA, INC. | Directeur/Membre du Conseil | 28/03/2022 |
Anciens postes connus de Angela Thedinga
| Sociétés | Poste | Fin |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Directeur Technique/Scientifique/R&D | 01/10/2021 |
| AVEXIS INC | Responsable des Ressources Humaines | 01/06/2019 |
Formation de Angela Thedinga
| Massachusetts Institute of Technology | Graduate Degree |
| MIT Sloan School of Management | Masters Business Admin |
| The University of North Carolina at Chapel Hill | Graduate Degree |
| University of Wisconsin | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| NKARTA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
